It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Philip D. Bonomi, MD

Patient Feedback
  • Oncology, Medical
  • Internal Medicine
Board Certification:
  • Medical Oncology
  • Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education: University of Illinois College of Medicine at Chicago
Residency: Geisinger Medical Center - Internal Medicine
Fellowship: Rush University Medical Center - Medical Oncology
Clinical Expertise:
  • Lung cancer
  • Mesothelioma
Research Interests:
  • Lung cancer
Google Map
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response.
    Ziel E, Hermann G, Sen N, Bonomi P, Liptay MJ, Fidler MJ, Batus M, Warren WH, Chmielewski G, Sher DJ
    J Thorac Oncol
    2015 Oct
  2. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.
    O'Mahony S, Nathan S, Mohajer R, Bonomi P, Batus M, Fidler MJ, Wells K, Kern N, Sims S, Amin D
    Am J Hosp Palliat Care
    2015 Feb 10
  3. Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer.
    Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P
    J Thorac Oncol
    2015 Feb
  4. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ
    Pract Radiat Oncol
    2014 Sep-Oct
  5. Circulating Angiogenesis Biomarkers Are Associated With Disease Progression in Lung Adenocarcinoma.
    Daly S, Kubasiak JC, Rinewalt D, Pithadia R, Basu S, Fhied C, Lobato GC, Seder CW, Hong E, Warren WH, Chmielewski G, Liptay MJ, Bonomi P, Borgia JA
    Ann. Thorac. Surg.
    2014 Oct 6
  6. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
    Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P
    2014 Nov 6
  7. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-small-cell Lung Cancer.
    Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK
    Clin Lung Cancer
    2014 Nov 18
  8. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
    Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ
    Am. J. Clin. Oncol.
    2014 Apr 28
  9. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.
    Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR
  10. Body Mass Index and Its Association with Clinical Outcomes for Advanced Non-Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials.
    Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH
    J Thorac Oncol
    2013 Sep
  11. Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection.
    Garg S, Gielda BT, Turian JV, Liptay M, Warren WH, Bonomi P, Sher DJ
    Pract Radiat Oncol
    2013 Oct-Dec
  12. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer.
    Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R
    J. Clin. Oncol.
    2013 Oct 21
  13. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.
    J Thorac Oncol. 2013
    2013 Mar
    8(3):338-45. doi: 10.1097/JTO.0b013e318282ded5.
  14. A multicenter Phase II study of ganetespib monotherapy in patients with genotypically-defined advanced non-small cell lung cancer.
    Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer JR, Chen LC, Sandler AB, Belani CP, Webb TR, Harper H, Huberman M, Ramalingham S, Wong KK, Teofilovici F, Guo W, et al.
    Clin Cancer Res. 2013
    2013 Apr 3. [Epub ahead of print]
  15. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.
    Sutton P, Borgia JA, Bonomi P, Plate JM
    Mol. Cancer
  16. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
    Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB.
    J Thorac Oncol. 2012
    2012 Oct
  17. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
    Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P.
    Anticancer Res. 2012
    2012 May
  18. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.
    Fidler MJ, Shersher DD, Borgia JA, Bonomi P.
    Ther Adv Med Oncol. 2012
    2012 Mar
    4(2):51-60. doi: 10.1177/1758834011427576.
  19. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
    Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, et al.
    Clin Cancer Res. 2012
    2012 Jun 1
    18(11):3163-9. doi: 10.1158/1078-0432.CCR-11-3090. Epub 2012 Apr 11.
  20. Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P.
    Clin Lung Cancer. 2012
    2012 Dec 20. doi:pii: S1525-7304(12)00263-X. 10.1016/j.cllc.2012.10.009. [Epub ahead of print]
  21. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L.
    Diagn Mol Pathol. 2012
    2012 Dec
    21(4):207-13. doi: 10.1097/PDM.0b013e31825554b2.
  22. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
    Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Nov 15
    81(4):985-91. doi: 10.1016/j.ijrobp.2010.06.059. Epub 2010 Oct 6.
  23. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer.
    Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi O, Mahon B, Coon JS, Warren WH, Faber LP, Hong E, Bonomi P, Liptay MJ, Borgia JA.
    Ann Thorac Surg. 2011
    2011 Nov
    92(5):1805-11; discussion 1811. doi: 10.1016/j.athoracsur.2011.06.058. Epub 2011 Sep 25.
  24. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
    Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM.
    J Clin Oncol. 2011
    2011 Mar 1
    29(7):909-16. doi: 10.1200/JCO.2010.31.6208. Epub 2011 Jan 31.
  25. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P.
    J Thorac Oncol. 2011
    2011 Jun
    6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.
  26. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers.
    Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon JS, DeCresce D, Thimothy L, Walters KA, Fhied C, Chang C, Chen SH, Faber LP, Bonomi P, Liptay MJ, Borgia JA.
    Int J Cancer. 2011
    2011 Jul 1
    129(1):133-42. doi: 10.1002/ijc.25644. Epub 2010 Nov 9.
  27. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients.
    Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, Faber LP.
    Ann Thorac Surg. 2011
    2011 Jul
    92(1):233-41; discussion 241-3. doi: 10.1016/j.athoracsur.2011.03.001. Epub 2011 May 28.
  28. Lung cancer: new developments point the way to reduced mortality.
    Bonomi P.
    Oncology (Williston Park). 2011
    2011 Jan
    25(1):82, 84. No abstract available.
  29. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer.
    Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ.
    Lung Cancer. 2011
    2011 Feb
    71(2):186-90. doi: 10.1016/j.lungcan.2010.05.006. Epub 2010 Jun 8.
  30. A multi-analyte serum test for the detection of non-small cell lung cancer
    Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA
    Br J Cancer
    2010 Oct 12
  31. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M, Fidler MJ, Bonomi PD.
    Expert Rev Anticancer Ther. 2010
    2010 Oct
    10(10):1589-99. doi: 10.1586/era.10.104. Review.
  32. Implications of key trials in advanced nonsmall cell lung cancer.
    Bonomi PD.
    Cancer. 2010
    2010 Mar 1
    116(5):1155-64. doi: 10.1002/cncr.24815. Review.
  33. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer.
    Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA.
    Clin Cancer Res. 2010
    2010 Jul 1
    16(13):3452-62. doi: 10.1158/1078-0432.CCR-09-3192. Epub 2010 Jun 22.
  34. Epidermal growth factor receptor pathway.
    Bonomi P.
    J Thorac Oncol. 2010
    2010 Dec
    5(12 Suppl 6):S470-1. doi: 10.1097/01.JTO.0000391370.86753.90. No abstract available.
  35. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J.
    Int J Cancer. 2010
    2010 Apr 1
    126(7):1630-9. doi: 10.1002/ijc.24896.
  36. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does side really matter?
    Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, Bonomi P, Liptay MJ.
    Ann Thorac Surg. 2009
    2009 Sep
    88(3):937-43; discussion 944. doi: 10.1016/j.athoracsur.2009.04.102.
  37. Apoptosis.
    Bonomi P.
    J Thorac Oncol. 2009
    2009 Nov
    4(11 Suppl 3):S1061-2. doi: 10.1097/ No abstract available.
  38. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer.
    Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH, Bonomi P, Liptay MJ.
    J Thorac Oncol. 2009
    2009 Mar
    4(3):338-47. doi: 10.1097/JTO.0b013e3181982abf.
  39. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
    Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR, Fletcher B, Dyehouse K, Ghalie R, Jazieh AR.
    Am J Clin Oncol. 2009
    2009 Jun
    32(3):269-73. doi: 10.1097/COC.0b013e318187dd40.
  40. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.
    J Clin Oncol. 2009
    2009 Jul 10
    27(20):3284-9. doi: 10.1200/JCO.2008.20.8181. Epub 2009 May 11.
  41. Treatment of locally advanced non-small cell lung cancer.
    Fidler MJ, Kim AW, Zusag T, Bonomi P.
    Clin Adv Hematol Oncol. 2009
    2009 Jul
    7(7):455-64, 479-80. Review.
  42. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
    Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P.
    J Thorac Oncol. 2009
    2009 Jul
    4(7):869-74. doi: 10.1097/JTO.0b013e3181a9a020.
  43. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV...
    Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC.
    Clin Lung Cancer. 2009
    2009 Jul
    10(4):252-6. doi: 10.3816/CLC.2009.n.035.
  44. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
    Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE.
    J Clin Oncol. 2008
    2008 Nov 20
    26(33):5407-15. doi: 10.1200/JCO.2008.17.3138. Epub 2008 Oct 20.
  45. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
    Einhorn LH, Bonomi P, Bunn PA Jr, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS.
    J Thorac Oncol. 2008
    2008 May
    3(5):545-55. doi: 10.1097/JTO.0b013e318170627f. No abstract available.
  46. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J.
    Lung Cancer. 2008
    2008 Jul
    61(1):82-90. doi: 10.1016/j.lungcan.2007.12.011. Epub 2008 Feb 5.
  47. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res. 2008
    2008 Apr 1
    14(7):2088-94. doi: 10.1158/1078-0432.CCR-07-4013.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.